Abstract
The fusion gene bcr-abl develops chronic myeloid leukemia (CML), and stimulates PI3K/Akt/mTOR signaling, leading to impaired autophagy. PI3K/Akt/mTOR signaling also plays an important role in cell metabolism. The Warburg effect is a well-recognized hallmark of cancer energy metabolism, and is regulated by the mTOR/c-Myc/hnRNP/PKM signaling cascade. To develop a new strategy for the treatment of CML, we investigated the associations among bcr-abl, the cascade related to cancer energy metabolism, and autophagy induced by a fatty-acid derivative that we had previously reported as being an autophagy inducer. Here we report that a fatty-acid derivative, AIC-47, induced transcriptional repression of the bcr-abl gene and modulated the expression profile of PKM isoforms, resulting in autophagic cell death. We show that c-Myc functioned as a transcriptional activator of bcr-abl, and regulated the hnRNP/PKM cascade. AIC-47, acting through the PPARγ/β-catenin pathway, induced down-regulation of c-Myc, leading to the disruption of the bcr-abl/mTOR/hnRNP signaling pathway, and switching of the expression of PKM2 to PKM1. This switching caused autophagic cell death through an increase in the ROS level. Our findings suggest that AIC-47 induced autophagic cell death through the PPARγ/β-catenin/bcr-abl/mTOR/hnRNP/PKM cascade.
Keywords:
Autophagy; Bcr-abl; Cell death; Fatty-acid derivative; Warburg effect.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / pharmacology*
-
Autophagy / drug effects*
-
Carrier Proteins / genetics
-
Carrier Proteins / metabolism*
-
Dose-Response Relationship, Drug
-
Energy Metabolism / drug effects
-
Fatty Acids / pharmacology*
-
Fusion Proteins, bcr-abl / genetics
-
Fusion Proteins, bcr-abl / metabolism*
-
Gene Expression Regulation, Neoplastic
-
Heterogeneous-Nuclear Ribonucleoproteins / metabolism
-
Humans
-
Isoenzymes
-
K562 Cells
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
-
Membrane Proteins / genetics
-
Membrane Proteins / metabolism*
-
PPAR gamma / metabolism
-
Proto-Oncogene Proteins c-myc / genetics
-
Proto-Oncogene Proteins c-myc / metabolism
-
Pyruvate Kinase / genetics
-
Pyruvate Kinase / metabolism*
-
RNA Interference
-
Signal Transduction / drug effects
-
TOR Serine-Threonine Kinases / metabolism
-
Thyroid Hormone-Binding Proteins
-
Thyroid Hormones / genetics
-
Thyroid Hormones / metabolism*
-
Transcription, Genetic
-
Transfection
-
beta Catenin / genetics
-
beta Catenin / metabolism
Substances
-
Antineoplastic Agents
-
CTNNB1 protein, human
-
Carrier Proteins
-
Fatty Acids
-
Heterogeneous-Nuclear Ribonucleoproteins
-
Isoenzymes
-
MYC protein, human
-
Membrane Proteins
-
PPAR gamma
-
Proto-Oncogene Proteins c-myc
-
Thyroid Hormones
-
abl-bcr fusion protein, human
-
beta Catenin
-
MTOR protein, human
-
Pyruvate Kinase
-
Fusion Proteins, bcr-abl
-
TOR Serine-Threonine Kinases